-
2023-507482-26-00
5
2024-10-04
Castrate-resistant prostate cancer with oligometastases on functional
-
2024-512872-36-00
5
2024-07-25
obstetric_pathological delivery
-
2023-504486-23-00
5
2024-05-29
Venous thromboembolism
-
2022-501710-62-02
6
2023-06-07
Peripheral T-cell lymphoma (PTCL)
-
2023-508594-84-00
4
2022-01-11
Metastatic pancreatic adenocarcinoma
-
2024-511001-28-00
4
2021-12-13
Neuroendocrine tumor
-
2024-514025-30-00
4
2021-03-25
Ocular conservative treatment for retinoblastoma
-
2024-516461-36-00
5
2021-01-27
Pregnancy associated hypertension, Pre-Eclampsia, Fetal growth restric
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2024-518578-15-00
5
2018-02-05
Is to demonstrate a non inferior efficacy of azithromycin and so the p
-
2024-517390-24-00
5
2011-04-26
Ovarian epithelial cancer : intraperitoneal resectable relapse
-
2024-516213-20-00
5
2025-03-25
Psoriatic arthritis
-
2024-514032-25-00
4
2024-12-11
Patients with a histilogically confirmed diagnosis of cervical squamou
-
2023-510178-15-00
5
2024-07-31
High-risk Large B-cell Lymphoma
-
2023-505515-21-00
5
2024-04-02
Giant Cell Arteritis
-
2023-505972-32-00
5
2024-02-26
locally advanced anal squamous cell carcinoma
-
2023-506139-13-00
5
2024-01-04
Treatment naïve patients with MF
-
2024-514644-93-00
5
2022-12-09
Metastatic renal cell carcinoma (mRCC) with a good or only one adverse
-
2023-505772-30-00
5
2022-11-09
Melanoma
-
2023-510097-14-00
5
2022-04-15
Patients with MMR deficient relapse or advanced / metastatic endometri
-
2024-513324-42-00
5
2022-03-23
Patent Foramen Ovale Closure
Atrial Arrhytmia or Tachycardia
-
2024-516096-32-00
4
2021-08-05
Platinum sensitive recurrent ovarian cancer
-
2023-507961-24-00
5
2021-04-19
High-Risk HER2-Positive Breast Cancer